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Introduction: Coronary artery bypass grafting (CABG) is performed to improve quality of life and to reduce
cardiac-related mortality and morbidity in patients with coronary artery disease (CAD). The aim of the present
observational study was to assess the performance of a new suture material (Optilene) for anastomosis con-
struction in CABG surgery using a routine clinical procedure. Performance was assessed using the incidence of
major adverse cardiac and cerebrovascular events (MACCE).
Methods: The study was designed as an international, multi-centre, prospective cohort study to evaluate the
safety and eﬃcacy of a new non-absorbable monoﬁlament for CABG surgery compared to data published in a
previous meta-analysis. Optilene suture was used to create the distal and proximal coronary artery anastomoses.
The primary endpoint was the cumulative MACCE rate up to discharge. Secondary parameters were in-
traoperative handling of the suture material and QoL up to 3 months after surgery. Patients were examined 30
days and 3 months postoperatively.
Results: In total, 199 patients were enrolled in 3 centres in Europe. The cumulative CABG adverse event rate up
to the day of discharge was 3%, in contrast to the 8.46% given by the data generated by Nalysnyk et al. A t-test
showed that our CABG rate was signiﬁcantly lower. QoL signiﬁcantly increased from preoperatively until 3
months after surgery. Ease of handling the suture material was rated as very good.
Conclusion: Optilene suture material represents a safe and eﬀective alternative to existing sutures used in CABG
surgery for anastomosis construction.
1. Introduction
Coronary artery bypass graft (CABG) surgery is one of the most
frequently performed elective surgical procedures [1]. CABG is a safe
concept and is routinely conducted in patients with coronary artery
disease (CAD) to improve quality of life and to reduce cardiac-related
mortality. CAD is the foremost leading cause of mortality in the Western
world and is the most common cause of heart failure. CABG was in-
troduced in the 1960s. Since then CABG surgery has become the most
studied intervention in the history of surgery. It is highly eﬀective in the
treatment of severe angina and delays unfavourable events such as
death, myocardial infarction and recurrence of angina. The randomized
clinical SYNTAX trial performed in the US and Europe has investigated
CABG surgery versus percutaneous coronary interventions (PCI) in
patients with left main coronary disease or three vessel disease [2].
Based on a 5 year follow-up the authors concluded that CABG surgery
should be the standard of care for patients with complex lesions (high
SYNTAX score (≥33) or intermediate (22–32) SYNTAX score). How-
ever for patients suﬀering from a less complex disease (e.g. left main
disease with low SYNTAX score 0–22 or intermediate 23–32 SYNTAX
Score or three-vessel disease with low SYNTAX Score 0–22), PCI is an
acceptable alternative to CABG [3].
The most frequently reported complications after CABG are myo-
cardial infarction (MI), stroke, death, graft stenosis and renal failure.
Thus, myocardial infarction, stroke, death, and repeat revascularisation
are deﬁned as major adverse cardiac and cerebrovascular events
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(MACCE). The recently published SYNTAX trial comparing CABG sur-
gery versus PCI in 1800 patients with multi-vessel disease or left main
disease reported the following 5 years complication rates for CABG:
myocardial infarction (3.8%), death (11.4%), stroke (3.7%), re-
vascularisation (13.7%), MACCE (26.9%) vs. PCI: myocardial infarction
(9.7%), death (13.9%), stroke (2.4%), revascularisation (25.9%),
MACCE (37.3%) [3].
In general, CABG operations are performed either on-pump or oﬀ-
pump. Several randomized controlled studies have been conducted
showing that “oﬀ-pump CABG” is as safe as on-pump surgery. Three
large studies (CORONARY trial, ROOBY trial, GOPCABE trial) have
intensively investigate the clinical outcome of oﬀ-pump versus on-
pump CABG surgery [4–9]. Lamy et al. reported no signiﬁcant diﬀer-
ence in the CORONARY trial involving 4752 patients, regarding the
composite primary outcome of death, stroke, myocardial infarction, and
renal failure at 30 days and 1 year after surgery in patients undergoing
oﬀ-pump versus on-pump CABG surgery [4,5]. But a trend toward more
repeat revascularisation was associated with the oﬀ-pump CABG (1.4%
vs. 0.8%). Therefore, a long-term follow-up of 5 years has been per-
formed in the CORRONARY study, supporting the previous data for the
composite outcome of death, stroke, myocardial infarction and renal
failure. Revascularisation rate after 5 years was 2.8% in the oﬀ-pump
group and 2.3% in the on-pump group, (p= 0.29) indicating no sig-
niﬁcant diﬀerence [6]. Further secondary endpoints of the CORONARY
study were economics and the Quality of life [6]. The 5 years result
showed a similar outcome regarding Quality of life for both techniques.
Also the costs per patient did not diﬀer between the procedures. Au-
thors of the CORONARY trial concluded that both procedures are
equally eﬀective and safe [6].
The ROOBY trial which enrolled a total of 2203 patients showed no
signiﬁcant diﬀerence between oﬀ-pump and on-pump CABG regarding
the composite primary endpoint (death or complications) at 30 days
postoperatively. In contrast, the 1 year and 5 year composite outcome
rate (death, repeat revascularisation, myocardial infarction) was higher
for the oﬀ-pump than for the on-pump CABG group (9.9% vs. 7.4%;
p=0.04 and 31.0% vs. 27.1%; p=0.046) respectively [7,8]. In ad-
dition, the 5 year survival rate was higher in the on-pump CABG group.
The ROOBY Investigators concluded that their 5 year results support
the ﬁndings of a Cochrane Systematic Review from 2012 that oﬀ-pump
CABG does not generally oﬀer any substantial advantages over on-
pump CABG, except possibly in unusual situations such as for example,
in patients with an extensively calciﬁed aorta, in which the oﬀ-pump
technique may result in less manipulation of the aorta, potentially de-
creasing the risk of aorta emboli or stroke [8].
The German GOPCABE trial randomly allocated 2539 elderly pa-
tients (≥75 years) either to on-pump or oﬀ-pump CABG surgery [9].
Primary combined endpoint was death, stroke, myocardial infarction,
repeat revascularization or new renal displacement therapy at 30 days
and 1 year after surgery. No signiﬁcant diﬀerence was observed within
30 days after surgery between both treatment groups in regard to the
composite endpoint (7.8% oﬀ-pump vs. 8.2% on-pump; p=0.74) or to
the individual components except for repeat revascularisation which
occurred more frequently in the oﬀ-pump group (1.3% vs. 0.4%,
p=0.04). At 12 months postoperatively the clinical outcome of the oﬀ-
pump group was similar to the on-pump showing no diﬀerence in the
composite endpoint (13.1% vs. 14.0%; p= 0.48) as well as in the in-
dividual components. Authors sum up that their ﬁndings do not support
the assumption that oﬀ-pump CABG can improve the early outcome in
high-risk patients. This is consistent with other scientiﬁc statements,
which conclude that both treatments may lead to an excellent clinical
result and that other factors, are more likely to inﬂuence the outcome
than the choice of the procedure [9].
The results of the meta-analysis published by Nalysnyk et al. served
as a basis for the conception of this observational study [10]. The meta-
analysis included subgroup analyses which were important for the de-
sign of the current observational study. Nalysnyk et al. [10] analysed
the in-hospital adverse events such as MI, stroke, death, gastrointestinal
bleeding (GI), renal failure, mortality and the 30-day mortality rate in
the following subgroups: studies performed in Europe, elective CABG,
cohort studies, multi-centric studies, and patients without a prior
CABG. The outcomes of these subgroup analyses were pooled and gave
the following complication rates for myocardial infarction (2.82%),
stroke (1.93%), GI bleeding (1.28%), renal failure requiring dialysis
(0.7%), mortality (1.72%) and 30-day mortality (2.1%), leading to a
cumulative MACCE rate of 8.46%, which served as the reference in the
present study.
The aim of the OPTICABG study was to assess the performance of a
new suture material (Optilene® B. Braun Surgical SA, Rubi, Spain) in
elective primary coronary artery bypass graft surgery performed using
routine clinical procedures in patients undergoing either on-pump or
oﬀ-pump surgery. The Optilene® suture consists of 95% polypropylene
and 5% polyethylene and, therefore, oﬀers increased ﬂexibility and
better handling compared to a pure polypropylene suture material.
Safety and eﬃcacy parameters commonly used in CABG surgery were
employed to evaluate the performance of the suture material. Safety
outcome was compared to the cumulative MACCE rate of 8.46% (re-
ference). If the results from the present study are equal to or better than
this reference, the suture material Optilene® can be regarded as a safe
and eﬀective alternative suture for CABG surgery.
2. Methods
The OPTICABG study is reported in accordance with the STROCSS
Guideline [11] which became a standard for the publication of cohort
studies in 2017.
2.1. Registration and ethics approval
In accordance with the Declaration of Helsinki, this cohort study
was registered with www.clinicaltrials.gov under the registration
number [NCT02546557]. The ﬁnal study protocol has been approved
by the Ethics Committees responsible for the participating clinics
(Ethics Committee, University Tübingen; Comité Ético de Investigación
Clinica, Hospital de la Santa Creu i Sant Pau; Ospedale Luigi Sacco,
Comitato Etico Interaziendale Milano Area A). Ethics approval was
needed to meet national requirements. A clinical study protocol was
developed a priori but not published in a peer-reviewed journal.
2.2. Study design
The study was designed as an international, multi-centre, pro-
spective, observational, single-arm cohort study. Enrolment took place
between November 2015 and February 2017 in three community hos-
pitals located in Germany (Robert Bosch Krankenhaus, Stuttgart), Spain
(Hospital de la Santa Creu i Sant Pau, Barcelona) and Italy (Ospedale
Luigi Sacco, Milano). Last patient out was in May 2017. Patients were
examined on the day of discharge, and on 30 days and 3 months after
surgery. Data collection and clariﬁcation were completed in July 2017.
Analysis was performed in August 2017 and a ﬁnal clinical study report
was completed in November 2017.
2.3. Population and intervention
Each centre included between 50 and 75 patients undergoing elec-
tive coronary artery bypass surgery for revascularisation. Patients were
treated in accordance with the local clinic standard; the distal and
proximal anastomoses were sutured using Optilene® suture material
manufactured by B. Braun Surgical SA, Rubi, Spain.
The suture material was applied by senior physicians, consultants
and residents who had been trained in, and were familiar with, the use
of the suture material. The participating surgeons selected the size of
the USP thread used. No control group was included. Subgroup analyses
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have not been performed.
2.4. Inclusion and exclusion criteria
Patients older than 25 years, scheduled for elective primary cor-
onary artery bypass graft surgery for the repair of a multi-vessel disease
or left main coronary disease using either on-pump or oﬀ-pump surgery
were eligible for this cohort study. All enrolled patients gave their
written informed consent to the scientiﬁc analysis of their pseudony-
mized data set in accordance with the Data Protection Law.
Exclusion criteria:
- Emergency surgery
- Insulin-dependent diabetes mellitus
- Acute myocardial infarction with CK-MB level> 10% of CK and/or
ECG signs
- Known immunodeﬁciency or immunosuppression
- Other combined aortic valve intervention except cardiac valve or
mitral valve surgery
- Participation or planned participation in another cardiovascular
study before study follow-up is completed
- Inability to give informed consent due to a mental disorder, learning
disability, or language barrier.
2.5. Recruitment and follow-up
Patients were recruited from the patient population treated at the
participating hospitals as part of daily clinical routine according to the
clinic's standard. No additional follow-up visits were performed for this
cohort study. Patients completed the study 3 months after surgery.
Regular monitoring visits were performed at all hospitals to ensure the
quality and validity of the data.
2.6. Sample size calculation
No sample size calculation was performed. A sample size of 200
patients was selected based on the number of patients that can be re-
cruited to a multi-centre, observational study within the reasonable
recruitment period of one year. This was considered adequate to detect
substantial deviations in eﬃcacy or safety compared to reference [9].
To avoid centre-speciﬁc eﬀects, a maximum of 100 patients could be
enrolled by one centre. The outcome of the current study was compared
to the results of a meta-analysis published by Nalysnyk et al., in 2003,
which provided post-CABG adverse event incidence and mortality rates.
According to the data of Nalysnyk et al. the cumulative incidence of
adverse events was calculated to be:
• Myocardial infarction (2.82%)
• Stroke (1.93%)
• GI bleeding (1.28%)
• Renal failure (0.70%)
• Mortality (1.72%)
The following subgroups were used for calculations by Nalysnyk
et al.:
• European population
• Elective CABG
• Cohort studies
• Multi-centric
• No prior CABG
The median group rates were used to compute the weighted mean
for each adverse event category as given above. A cumulative incidence
of 8.46% was obtained for the adverse events in question. In regard to
this value, the current study had a power of 83.9% to detect a 75%
increase in the cumulative risk. If the data from the current observa-
tional study did not diﬀer signiﬁcantly from the published data, the
suture material Optilene® could be regarded as safe and eﬀective for
CABG surgery.
2.7. Statistical methods
All statistical tests were performed two-tailed with the pre-speciﬁed
signiﬁcance level of α=5%. A conﬁrmatory statistical test was per-
formed for the primary endpoint; exploratory statistical tests were
performed if appropriate for evaluation of eﬀects of interest. Analysis
was performed using SAS 9.4 software (SAS Inc., Cary, NC).
2.8. Outcomes
Primary variable was the incidence of early in-hospital CABG ad-
verse events occurring up to the day of discharge. In-hospital CABG
adverse events were myocardial infarction, stroke, death, GI bleeding
and renal failure.
2.8.1. Secondary variables were divided into safety and eﬃcacy parameters
Safety parameters:
- Incidence of the individual components of in-hospital CABG adverse
events up to day of discharge (death, stroke, MI, renal failure, GI
bleeding)
- Incidence of stroke, MI up to 30 days ± 10 days and 3 months ± 2
weeks postoperatively
- Incidence of the 30-day±10 days and 3-month± 2 weeks mor-
tality rates
- Anastomosis revision due to anastomotic bleeding or other causes
Eﬃcacy parameters:
- Frequency of repeat revascularisation leading to CABG or PIC 30
days ± 10 days and 3 months ± 2 weeks postoperatively
- Quality of life 3 months ± 2 weeks postoperatively
- Intraoperative handling of the suture material
- Length of postoperative hospital stay
Quality of life was rated by the patients using the EQ-5D-5L ques-
tionnaire preoperatively, 30 days postoperatively and 3 months after
surgery. EQ-5D-5L was used in the German, Spanish, Italian language
and the sponsor has taken up a license at the EuroQol Group. EQ-5D is a
standardised measure of health status developed by the EuroQol Group
to provide a simple, generic measure of health for clinical and economic
appraisal. EQ-5D is designed for self-completion by respondents and
takes only a few minutes to complete. Instructions to respondents are
included in the questionnaire. EQ-5D-5L consists of 2 pages – the de-
scriptive system and the EQ Visual Analogue Scale (EQ-VAS). The de-
scriptive system comprises 5 dimensions (mobility, self-care, usual ac-
tivities, pain/discomfort, anxiety/depression). Each dimension has 5
levels: no problems, slight problems, moderate problems, severe pro-
blems and extreme problems. The EQ VAS records the respondents self-
rated health on a 20 cm vertical, visual analogue scale with endpoints
labelled “the best health you can imagine, points= 100” and “the worst
health you can imagine, points= 0”.
Assessment of the intraoperative handling of the suture material
was performed using a ﬁve-point Likert Scale (1 worst - 5 best). The
following dimensions were evaluated: Knot security, elasticity, feel,
tissue drag, and knot pull strength.
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3. Results
3.1. Recruitment
More than 200 patients were screened. Inclusion of the ﬁrst patient
was performed on 30th November 2015. Recruitment of 199 patients
was completed on 17th February 2017. Last patient out was completed
on 8th May 2017.
Finally, the data set containing 199 patients was analysed. A ﬂow
chart is not provided due to the single-arm design of this cohort study.
One hundred and ninety-six patients were examined up to the day of
discharge. The visit 30 days after surgery was performed for 188 pa-
tients because one patient died and the data of two patients were
missing on the day of discharge. Between operation and 30 days post-
operatively, a total of two deaths occurred and nine patients were lost
to follow-up. A total of 191 patients were examined 3 months post-
operatively. In total, 6 patients died from surgery up to 3 months
postoperatively, and 2 patients were lost to follow-up at the 3-month
visit.
3.2. Demography
A total of 154 men and 45 women were included. A mean BMI of
27.98 ± 4.23 kg/m2 was observed in the OPTICABG cohort [min.
18.37 kg/m2 – max. 44.98 kg/m2]. The average age was 67.24 ± 10.11
years [min. 39 years – max. 89 years]. Further baseline characteristics
and reasons for surgery are shown in Tables 1 and 2.
3.3. Intraoperative and surgical details
In total, 24 surgeons participated in the study; 12 surgeons in the
German hospital, and 6 surgeons each in the Italian and Spanish clinics.
Most of the operations were performed by consultants (N= 148); only
33 interventions were performed by head physicians, and residents
were involved in 18 operations. In total, 94% of the patients underwent
a sternotomy; the remaining patients underwent minimally invasive
surgery (mini-thoracotomy). This type of minimally invasive interven-
tion was performed by all centres (10% Germany, Italy and Spain 4%
each). In total, 58% of the patients underwent oﬀ-pump surgery, 40%
on-pump surgery and 2% of the operations started oﬀ-pump and were
then converted to on-pump surgery. In Germany, 91% of the inter-
ventions were performed oﬀ-pump, whereas on-pump surgery was
preferred in Italy (67%) and Spain (58%). CABG surgery took on
average 209.03min ± 59.08min [min. 50 min – 420min].
3.4. Anastomosis and bypass details
In total, 544 bypass interventions were performed in 199 patients.
The average number of bypasses per patient was 3 [min. N=1 – max.
N=6]. The LIMA was used as graft material in most of the bypasses
followed by a radial artery, the RIMA and the saphenous vein. The
LIMA was used as graft material in 95% of the patients.
The total number of anastomoses was 708; distal N=544 and
proximal N=164. To construct the anastomosis, Optilene suture ma-
terial was applied using USP 8/0, USP 7/0 or USP 6/0. The clinics in
Germany and Spain preferred USP 8/0, whereas USP 7/0 was mainly
used in Italy. USP size 6/0 was only used for proximal anastomoses not
for distal anastomoses. The average number of applied suture threads
per cardiac operation was 4 [min. N= 1 – max. N=7].
The most often used vessel for distal anastomosis construction was
the LAD (34%), followed by the CxMarg I (21%), the PDA (18%), the
CxMarg II (11%), and DG I (10%). The LIMA was anastomosed to the
LAD in 92% of the patients. All proximal anastomoses used either the
LIMA (sequential bypass; N=121 anastomoses) or the aorta (N=36
anastomoses), or others (N=7).
3.5. Outcomes
3.5.1. Primary outcome
Primary outcome was the incidence of early in-hospital CABG ad-
verse events occurring up to day of discharge. In-hospital CABG adverse
events were myocardial infarction, stroke, death, GI bleeding and renal
failure.
Six CABG events occurred up to discharge: one death (haemorrhagic
shock), two myocardial infarctions and three renal failures, leading to a
CABG event rate of 3%; CI 95% [1.1%–6.5%]. This rate was compared
to the literature reference of Nalysnyk et al. that showed a cumulative
CABG event rate of 8.46% up to day of discharge. The reference value of
8.46% lies outside the corresponding 95% conﬁdence interval for the
OPTICABG study; thus, the 3% CABG event rate observed in the OPT-
ICABG study was signiﬁcantly lower.
In addition, we also compared our in-hospital MACCE adverse rate
to the MACCE rate of the CABG group published in the SYNTAX trial in
Table 1
Baseline characteristics.
N Percentage [%]
Smoker 46 23
ASA:
ASA I 36 18
ASA II 38 19
ASA III 123 62
ASA IV 2 1
Hypertension 142 71
COPD 24 12
Stroke 12 6
Diabetes 60 30
Risk for renal insuﬃciency 15 8
Hyperlipidemia 141 71
Sinus rhythm 189 95
Atrial ﬁbrillation 10 5
Left ventricular ejection fraction:
< 21% 1 0.5
21%–30% 9 5
31%–50% 33 17
>50% 156 78
Table 2
Cardiac disease and reason for surgery.
N
Left main disease only 4 (2%)
Left main disease in combination a single vessel disease 0
Left main disease in combination with a double vessel disease 3 (1%)
Left main disease in combination with a multi vessel disease 20 (10%)
Single vessel disease only 17 (9%)
Double vessel disease only 32 (16%)
Multivessel disease only 123 (62%)
NYHA I 52 (26%)
NYHA II 95 (48%)
NYHA III 51 (25%)
NYHA IV 1 (1%)
Combined surgery no 167 (84%)
Combined with aortic valve replacement 16 (8%)
Combine with mitral valve repair 7 (3.5%)
Combined with mitral valve replacement 5 (2.5%)
Combined with aortic replacement, mitral valve repair 1 (0.5%)
Others 3 (1.5%)
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2009 [12].Within the SYNTAX trial the MACCE rate was deﬁned as the
combination of the death, stroke, myocardial infarction and re-
vascularisation. Therefore, we performed an analysis of the same
MACCE adverse event combination in our study. The following MACCE
rate were reported for the SYNTAX CABG group: until discharge (in-
hospital) 5.4%, in our study we observed a MACCE rate (1 death, 2
myocardial infarctions, 1 revision due to malfunction of the bypass; 4/
199 patients) of 2.0% CI 95% [0.55%–5.1%] until discharge (in-hos-
pital). Indicating that our MACCE rate was lower than in the SYNTAX
trial, because the upper limit of our CI does not included 5.4%.
3.5.2. Secondary outcome: safety and eﬃcacy parameters
3.5.2.1. Safety. One additional patient died (sepsis) within 30 days
after surgery, and the total CABG rate increased to 3.5%, CI 95%
[1.4%–7.2%]. By the end of the study, a total of six deaths, three
myocardial infarctions and four renal failures were recorded, indicating
a CABG rate of 9.8%; CI 95% [5.3%–16%] at 3 months after surgery
(Table 3).
Reason for death was reported as follows: 2 x sepsis, 1 x respiratory
failure, 1 x haemorrhagic shock, 1 x stroke and 1 x resuscitation.
Total number of adverse events was 48 in the OPTICABG study.
Death rate was 4.5% (N=6), renal failure rate 2.0% (N=4), myo-
cardial infarction rate 1.5% (N=3). One stroke occurred at the 3-
month follow-up and resulted in death. Therefore, this stroke was re-
corded under the death rate.
Reoperation was necessary in eight patients. In six patients this was
due to a problem with the sternal wound; one revision was performed
due to malfunction of the bypass; in another case, cardiac intervention
with aortic valve replacement was necessary.
Postoperative bleeding, mainly haematomas with no causal re-
lationship to the anastomosis, was seen in three patients resulting in
further surgical interventions. A PCI was reported in 2 patients post-
operatively.
Superﬁcial wound infections classiﬁed as A1 were observed in four
cases (2%) and a deep wound infection classiﬁed as A2 was seen in two
patients (1%). Treatment was antibiotics. Number of other health dis-
orders was 16 (data not shown).
Most of the adverse events were resolved (30/48): 8/48 AEs were
resolved with sequelae; 2/48 were ongoing; for 2/48 the status was not
recorded; and 6 events lead to death. In total, 31/48 AEs were rated as
serious. Only 2 of the AEs reported were associated with the applied
suture material (2 threads ruptured during knotting).
3.5.2.2. Eﬃcacy. Length of postoperative hospital stay was
9.42 ± 5.03 days. A mean duration of 2.60 ± 2.38 days. [min. 1 –
max. 17 days] was recorded for the stay in the intensive care unit.
Assessment of the intraoperative handling of the suture material
was performed using a ﬁve-point Likert Scale (1 worst - 5 best). All
dimensions were predominantly evaluated with four points, indicating
that handling of the suture material is excellent and well-suited for
CABG surgery (Fig. 1).
Quality of life was rated by the patient using the EQ-5D-5L ques-
tionnaire preoperatively, 30 days postoperatively and 3 months after
surgery (“the best health you can imagine, points= 100” and “the
worst health you can imagine, points= 0”).
Preoperatively, the patients assessed their health as 65 ± 15.95
points. At 30 days postoperatively, this had increased to 70 ± 16.51
points, and to 80 ± 15.44 points at assessment 3 months after surgery
(Fig. 2). A t-test indicated that Quality of life was signiﬁcantly improved
3 months after surgery compared to status at screening. Further sub-
group analysis of the ﬁve variable dimensions showed no signiﬁcant
diﬀerence at diﬀerent time points.
3.6. Employment status
Employment status is recorded in Table 4. The total population
consisted of approximately 50% retirees. More patients were able to
work full-time from 30 days postoperative up to 3 months after surgery.
Only 5% of the patients were unable to work 3 months postoperatively.
4. Discussion
CABG surgery is described as a safe concept and is a routinely
performed operation in patients with coronary artery disease. It is the
most common surgical procedure performed on the heart. Alexis Carrel
described the principles of the CABG in 1910. In 1953, J. Gibbon per-
formed the ﬁrst heart-lung bypass and, in 1968, R. Favaloro used a
saphenous vein graft for the ﬁrst time as the coronary artery bypass
graft. In the 1960s, the clinic of Kolesov was the only one in the world
regularly performing CABGs. The ﬁrst LITA graft performed on a
beating heart was reported by Kolesov in 1964, but was soon aban-
doned [13].
In the 1990s this type of intervention underwent a revival after the
work of Benetti.
Common, reported complications of CABG surgery are mortality
(2–4%), myocardial infarction (2–4%), renal failure (30%), and
bleeding (4–6%). The present prospective, international, multi-centric,
observational cohort study was undertaken to assess the performance of
a new suture material (Optilene®) in coronary artery bypass graft sur-
gery using routine clinical procedures. The outcomes of subgroup
analyses from the results published by Nalysnyk et al., in 2003 were
pooled and gave the following complication rates for myocardial in-
farction (2.82%), stroke (1.93%), GI bleeding (1.28%), renal failure
(requiring dialysis (0.7%), mortality (1.72%) and 30-day mortality
(2.1%). The cumulative incidence of these CABG adverse events up to
day of discharge was 8.46% which served as a reference in the current
study. Our hypothesis was that if our MACCE rate is lower or equal to
the reference rate, the suture material Optilene® can be regarded as a
safe and eﬃcient alternative to the existing sutures used for CABG
surgery.
Cumulative CABG adverse event rate up to day of discharge was 3%
in the present study compared to 8.46%. A t-test demonstrated that our
CABG rate was signiﬁcantly lower. Comparison of the incidence of in-
dividual CABG adverse events up to discharge also showed lower re-
ported complication rates. Furthermore, the 30-day mortality rate was
1.0% in the current study and therefore lower than the reference value
at 30 days postoperatively (2.1%). In addition, only one reoperation
due to malfunction of the bypass was needed (0.5%) in the study group.
An infection in the sternal wound was observed in 3% of the patients,
and no anastomotic bleeding was seen. Only one stroke (1/197, 0.5%)
occurred at 3 months postoperatively which led to death.
Comparison of the OPTICABG MACCE rate to the MACCE rate of the
SYNTAX study published in 2009 [12], indicated that our MACCE rate
until discharge was lower than in the SYNTAX trial 2.0% vs. 5.4% and
comparable at 30 days postoperatively 2.5% vs. 5.2%, respectively.
In regard to safety, the type of adverse events – with varying se-
verity and frequency – reported in the OPTICABG study are very
common in patients with underlying conditions as encountered in this
non-interventional study. Therefore, by using the mentioned parameter
we could demonstrate the safety of Optilene® suture material for CABG
Table 3
Safety parameters.
Complication Discharge 30 days 3 months Total
Death 1 (0.5%) 1 4 6 (4.5%)
Stroke 0 (0%) 0 0 0 (0%)
Myocardial Infarction 2 (1.0%) 0 1 3 (1.5%)
Renal failure 3 (1.5%) 0 1 4 (2.0%)
GIT bleeding 0 (0%) 0 0 0 (0%)
Total 6 (3.0%) 1 6 13 (9.8%)
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surgery.
In total, 708 anastomoses were constructed using Optilene® suture
material with varying USP sizes. Handling of the suture thread was
rated as very good. Quality of Life (QoL) signiﬁcantly increased from
preoperatively to 3 months postoperatively and the increase was in-
dependent of the hospital, the type of operation (oﬀ-pump or on-pump)
or the type of chest opening (sternotomy or minimally invasive).
A typical population with cardiac disease was treated in our study.
No severe risk factors could be identiﬁed. Hyperlipidaemia was re-
ported in 71% of patients which is quite normal in this type of patient
cohort. Hyperlipidaemia is the main reason for arteriosclerosis and
calciﬁcation of the arterial vessels resulting in decreased blood supply.
Similarly to the literature, the LIMA was also predominantly used as
graft material in our study. In most cases this was anastomosed to the
LAD because these vessels have the same lumen and their character-
istics match very well. Sternotomy was the preferred technique for
opening the chest, but the minimally invasive approach was selected in
6% of the patients. The number of patients receiving oﬀ-pump or on-
pump surgery were not signiﬁcantly diﬀerent, but a centre-speciﬁc ef-
fect in regard to oﬀ-pump surgery was noticed in Germany, where 91%
of the interventions were performed as oﬀ-pump surgery in contrast to
Italy (33%) and Spain (41%). Numerous surgeons (N=24) with var-
ious functions located in three diﬀerent European hospitals performed
the cardiac surgery in a representative study population using daily
routine clinical procedures. This indicates high transferability and
generalisation of our clinical results. Nonetheless, our study has some
limitations, such as the use of a historical control group and a short-
term postoperative follow-up. A further weakness is the small cohort
size.
In conclusion the OPTICABG study, which is a single-arm, multi-
centre, international, prospective study has shown that the use of the
Optilene® suture consisting of polypropylene 95% and polyethylene 5%
is safe and eﬃcient for CABG surgery in an unselected broad patient
population with a cardiac disorder treated in clinical practice using
either on-pump or oﬀ-pump surgery interventions. Therefore Optilene®
suture represents a viable alternative for CABG interventions.
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Abbreviation list
AE Adverse Event
ASA American Society of Anaesthesiologists - Physical Health
Status
BMI Body Mass Index
CABG Coronary Artery Bypass Graft
CAD Cardiac Artery Disorder
COPD Chronic Obstructive Pulmonary Disease
CxMarg Left Circumﬂex Artery Marginal Branch
DG Diagonal Artery
LAD Left Anterior Descending Artery
LIMA Left Internal Mammary Artery
NYHA New York Heart Association
PDA Posterior Descending Artery
PMCF Post Market Clinical Follow up
QoL Quality of Life
RIMA Right Internal Mammary Artery
RA Radial Artery
SAE Serious Adverse Event
SVG Saphenous vein graft
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